APAC Radiopharmaceuticals Market - Industry Trends and Forecast to 2030
The Asia-Pacific radiopharmaceuticals market is expected to reach USD 2,733.43 million by 2030 from USD 1,756.76 million in 2022, growing at a CAGR of 5.7% during the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market SegmentationAsia-Pacific Radiopharmaceuticals Market, By Type (Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals), Application (Diagnostic and Therapeutic), Source (Nuclear reactors and Cyclotrons), End User (Hospitals, Diagnostic Centers, Cancer research institutes, Ambulatory surgical centers, and Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific Radiopharmaceuticals Market DynamicsDriver
• Growing demand for radiopharmaceutical among diagnostics and clinical use
Restraint
• Potential risks associated with radiopharmaceuticals
Opportunity
• Rising research and development expenditure of radiopharmaceuticals
Market PlayersSome of the major market players operating in the Asia-Pacific radiopharmaceuticals market are:• Cardinal Health
• Advanced Accelerator Applications, A Novartis Company
• Lantheus
• Curium Inc
• GENERAL ELECTRIC COMPANY
• Jubliant Radiopharma, A Jubilant Pharma Company
• China lsotope & Radiation Corporation
• Bracco
• NTP
• Eckert & Ziegler
• SHINE Technologies, LLC
• Eczacıbaşı-Monrol
• IBA Worldwide
• Global Medical Solutions
• BWX Technologies. Inc
• Institute of Isotopes
• Coqui Radiopharmaceuticals Corp,
• Evergreen Theragnostics, Inc.
• Isotope JSC
• PharmaLogic Holdings Corp
• Siemens Healthcare GmBH